Invacare Corp. (NYSE:IVC) CEO A. Malachi Mixon III, a name synonymous with the company since he bought it with his life savings in 1979, is stepping down from his chief executive post but will stay on as chairman.
The chief executives of healthcare companies are among the best paid in industry, according to a Wall Street Journal survey.
Boston Scientific Corp. (NYSE:BSX) CEO Raymond Elliott ranked eighth on the newspaper’s list, earning $32.1 million last year. That’s a princely sum to be sure, but includes a hefty signing bonus and other, long-term awards.
Thermo Fisher Scientific Inc. (NYSE:TMO) CEO Marc Casper edged Elliott out for the seventh spot with $33.0 million in 2009
Neoprobe Corp. (OTC:NEOP) hired a biotechnology and pharmaceuticals industry veteran as its chief development officer.
Mark Pykett, 46, is stepping into the role, which calls for him to assist the company with its product and business development, partnering and investor relations efforts, according to a press release from the Dublin, Ohio-based firm.
- Covidien pharma president Wright bows out
Timothy Wright resigned as Covidien plc’s (NYSE:COV) senior vice president and president of its pharmaceuticals segment, effective Dec. 2, according to a Securities & Exchange Commission filing. Pharma CFO Matthew Harbaugh will serve as interim president of the segment until Wright’s successor is found, according to the filing.
Ivan Trifunovich will be occupying the corner office at Helicos BioSciences Corp. (NSDQ:HLCS), as the company rolls out a new licensing program for its single-molecule gene sequencing technology.
Trifunovich, formerly a senior consultant to the Helicos board, was elected to serve as executive chairman Sept. 15. He replaces interim CEO Ronald Lowy, who took over from Stephen Lombardi in February and will remain a board member.
A roundup of personnel changes by medical device, diagnostics and life science companies around the nation:
Medtronic Inc.’s (NYSE:MDT) cardiology group yielded a new director for medical technology company SurModics Inc. (NSDQ:SRDX)
Scott Ward, a former Medtronic senior vice president and president of the company’s CardioVascular business, joined SurModics’ board, bringing its number to nine.